Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by Zacks Research

Key Points

• Zacks Research downgraded Amneal Pharmaceuticals from “hold” to “strong sell,” despite the broader analyst consensus remaining “Moderate Buy,” with nine buy ratings and one sell rating and a $21.00 consensus price target.
• Amneal shares opened at $19.65 after falling 3.2%; the stock has traded between $9.56 and $21.17 over the past year and has a market capitalization of approximately $6.28 billion.
• Company insiders have sold 413,016 shares worth about $7.2 million over the past 90 days, while institutional ownership stands at 31.82%. Amneal most recently beat quarterly EPS estimates, reporting $0.30 versus the $0.24 consensus.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a note issued to investors on Tuesday, Zacks reports.

AMRX has been the subject of a number of other research reports. UBS Group reiterated a "buy" rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Weiss Ratings raised shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 26th. Oppenheimer assumed coverage on shares of Amneal Pharmaceuticals in a report on Wednesday, September 23rd. They set an "outperform" rating and a $27.00 price target for the company. Wall Street Zen raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Amneal Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Amneal Pharmaceuticals Stock Down 3.2%

Shares of NASDAQ AMRX opened at $19.65 on Tuesday. The firm's 50-day moving average is $18.40 and its two-hundred day moving average is $15.84. The company has a market capitalization of $6.28 billion, a PE ratio of 40.10, a price-to-earnings-growth ratio of 2.38 and a beta of 1.22. Amneal Pharmaceuticals has a 12-month low of $9.56 and a 12-month high of $21.17. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.06. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the sale, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. The trade was a 85.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John Kiely sold 50,000 shares of the company's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the transaction, the director directly owned 210,252 shares of the company's stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio acquired a new position in Amneal Pharmaceuticals during the second quarter worth approximately $29,000. KBC Group NV acquired a new position in shares of Amneal Pharmaceuticals in the 1st quarter valued at $80,000. Strs Ohio grew its stake in shares of Amneal Pharmaceuticals by 158.5% during the 1st quarter. Strs Ohio now owns 10,600 shares of the company's stock valued at $132,000 after buying an additional 6,500 shares during the period. Walleye Capital LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 1st quarter valued at $133,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Amneal Pharmaceuticals during the 1st quarter worth $136,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.